Investing Strategy

Two events, eight days apart, have moved the Fed from a stable hold to what markets now treat as better than even odds of a hike on September 16. For portfolios built on the assumption that the next Fed move would be down, this week forces a rethink.

The combined message is no longer whether spending continues, it clearly does, but whether the returns show up on a timeline investors are willing to fund.

SpaceX approaches its first lock up window, the Magnificent Seven deliver a divided earnings season, and the yen gives back half its intervention gains. Three separate stories, one common thread of supply and demand.

A patent cliff worth hundreds of billions in pharma revenue, a record dealmaking cycle, and a multi year base finally cleared on the charts are converging into the sector's strongest stretch since the pandemic era.

For most of the first half of 2026, semis and memory stocks led the rally while the Magnificent Seven lagged. The story has flipped.

The mainland rally has closed much of the discount that defined Chinese equities for years. What is left is a market trading close to its own history rather than below it, and a widening menu of access routes that Indian investors will need to read carefully.

In 2026, the more interesting question is the one investors largely stopped asking: how much of the developed world outside the United States belongs in your portfolio, and which instrument do you use to get there?

South Korea's benchmark has doubled in 2026, triggered two circuit breakers, and now sits at the centre of the global AI hardware trade. What is driving it, what just broke it, and what comes next.

Two trillion dollars in market capitalisation erased. A venerable ETF in a technical bear market. Oracle punished for beating estimates. Accenture down 16% in a day. The market has decided software is the turkey at the AI banquet. The data tells a more complicated, and more investable, story.